

# Novo Nordisk Minnesota State Insulin Affordability Program Refill/Change Request Form

**Health Care Practitioner:** Use this form to request a refill, add a new medication, request a change in medication, change the dosage of a current medication, or to update your health care practitioner's contact information.

This form must be submitted directly by the HCP and must include a cover letter/HCP letterhead to clearly identify HCP as the sender.

Check all that apply:

**New medication** 

**Medication change** 

HCP address or information change Other \*Asterisks indicate required field. Do not leave blank.

Section J: Patient Information						
Patient First Name*:	Patient Last Name*:		DOB*:			
Known Drug Allergies*:						
Patient Street Address*:						
City*:	State*:	ZIP*:				
Datiant Emails						

Patient Email:

## Section K: Health Care Practitioner Information

Licensed Health Care Provider (All medication is shipped to patient's address. No PO Box permitted.)						
Prescriber First Name*:		Prescriber Last Name*:				
Designation:						
Street Address*:						
Suite/Building/Floor#:						
City*: St		State*:		ZIP*:		
Phone*:		State License Nur	ber#*:		State Where Licensed:	
Fax*:	Offic	ce Contact:		Office Email:		
NPI*:	Days	s Office is Closed fo	r Deliveries:			

# Section L: Health Care Practitioner Declaration

Health Care Practitioner Declaration: "My signature certifies that I am a licensed health care practitioner eligible under state law to prescribe, receive, and dispense the requested medication(s) listed on the attached order, shipped from Novo Nordisk, and that I am not prohibited from participating in federally funded health care programs. If I am a Nurse Practitioner, Physician Assistant, Pharmacist, or PharmD, I certify that I am authorized and eligible in the state within which I am currently practicing to prescribe, receive, and dispense these products, and that I have my supervising Physician's approval to do so if required by law. Note: Prescribing practitioner information must match practitioner's signature. I also certify that the product(s) being prescribed are to treat diagnosis(es) consistent with indication(s) and dosing described in the product's prescribing information. I further certify that all information provided in the Licensed Health Care Practitioner Information section is correct. I agree that medication(s) provided to me by Novo Nordisk for the applicant named in the Applicant Informatiwon section will be provided by me to such eligible applicant for his or her own use without charge. I will not otherwise use any of such medications or prescribe, provide or dispense all or any portion thereof for the use of any other person. I consent that Novo Nordisk may contact the applicant named in the Applicant Information section for verification of applicant status and receipt of the indicated medication(s). I further consent that Novo Nordisk may, at its discretion and with adequate notice, perform an on-site audit/review solely related to Novo Nordisk Diabetes Patient Assistance Program (PAP) records related to the applicant named above on this application. I understand that I am not eligible to seek reimbursement for any medication dispensed by PAP, from any government program or third-party insurer and will not apply any Novo Nordisk medication, provided by PAP, towards the applicant's True-Out-Of-Pocket (TrOOP) costs. I also understand that eligibility under PAP is subject to Novo Nordisk's discretion and that Novo Nordisk reserves the right to modify or terminate PAP at any time. Finally, I certify that I receive no direct or indirect payments related to PAP."

## PLEASE DO NOT INCLUDE PATIENT MEDICAL RECORDS.

## Phone: 866-310-7549 M-F 8am-8pm ET Novo Nordisk, Inc. PO Box 370 Somerville, NJ 08876 Fax: 866-441-4190

Fiasp<sup>®</sup>, FlexPen<sup>®</sup>, FlexTouch<sup>®</sup>, NovoFine<sup>®</sup>, Novolin<sup>®</sup>, NovoLog<sup>®</sup>, NovoPen Echo<sup>®</sup>, PenFill<sup>®</sup>, Tresiba<sup>®</sup>, and Zegalogue<sup>®</sup> are registered trademarks of Novo Nordisk A/S. Novo Nordisk is a registered trademark of Novo Nordisk A/S.

© 2025 Novo Nordisk All rights reserved. Version 1 February 2025



# Novo Nordisk Minnesota State Insulin Affordability Program Refill/Change Request Form

#### \*Asterisks indicate required field. Do not leave blank.

Patient First Name*:	Patient Last Name*:	DOB*:
Prescriber First Name*:	Prescriber Last Name*:	NPI*:

Product*	Max Dose/Day (units)	Sig/Directions*	Formulation* Cart = Cartridge		Qty	
Insulin						
Tresiba® (insulin degludec) injection U-100			Vial	FlexTouch®		
Insulin Degludec Injection U-100 (UB)			Vial	FlexTouch®		
Tresiba® (insulin degludec) injection U-200			FlexTouch®			
Insulin Degludec Injection U-200 (UB)			FlexTouch®			
Fiasp® (insulin aspart) injection 100 U/mL			Vial	FlexPen®	Cart	
NovoLog <sup>®</sup> (insulin aspart) injection 100 U/mL			Vial	FlexPen®	Cart	
Insulin Aspart Injection 100 U/mL (UB)			Vial	FlexPen®	Cart	
Novolin <sup>®</sup> R (insulin human) injection 100 U/mL			Vial	·		
<b>Novolin® N</b> (insulin isophane human) injectable suspension 100 U/mL			Vial			
NovoPen Echo®		1 pen				
<b>NovoLog<sup>®</sup> Mix 70/30</b> (insulin aspart protamine and insulin aspart) injectable suspension 100 U/mL			Vial	FlexPen®		
Insulin Aspart Protamine and Insulin Aspart Injectable Suspension Mix 70/30 100 U/mL (UB)			Vial	FlexPen®		
<b>Novolin® 70/30</b> (insulin isophane human and insulin human) injectionable suspension 100 U/mL			Vial			
Other						
Zegalogue® (dasiglucagon) injection 0.6 mg/0.6 mL		Auto-injector 1-pack Prefilled Syringe 1-pack	Auto-injector 2-pack Prefilled Syringe 2-pack			
Needles						
NovoFine® 32G 6mm (100 needles/box)						
FlexPen®/FlexTouch® are used with Novo Nordisk disposable needles. Needles will not be sent as part of the PAP order if they are not requested.					sted.	
By signing below, I acknowledge that I have read and agree to the Health Care Practitioner Declaration on page 1. Products are dispensed as written. (Handwritten/valid electronic signatures accepted; no photocopies, power of attorney, or stamped signatures allowed.)						

Practitioner Signature\*:

Date\*:

### PLEASE DO NOT INCLUDE PATIENT MEDICAL RECORDS.

### Phone: 866-310-7549 M-F 8am-8pm ET Novo Nordisk, Inc. PO Box 370 Somerville, NJ 08876 Fax: 866-441-4190

Fiasp<sup>®</sup>, FlexPen<sup>®</sup>, FlexTouch<sup>®</sup>, NovoFine<sup>®</sup>, Novolin<sup>®</sup>, NovoLog<sup>®</sup>, NovoPen Echo<sup>®</sup>, PenFill<sup>®</sup>, Tresiba<sup>®</sup>, and Zegalogue<sup>®</sup> are registered trademarks of Novo Nordisk A/S. Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2025 Novo Nordisk All rights reserved.

Version 1 February 2025